v3.26.1
Stockholders' Equity - Additional Information (Details) - USD ($)
 6 Months Ended 12 Months Ended
Aug. 10, 2026
Feb. 10, 2026
Feb. 09, 2026
Nov. 10, 2025
Oct. 07, 2024
Jun. 30, 2026
Dec. 31, 2025
May 21, 2026
Feb. 08, 2026
Subsidiary Sale Of Stock [Line Items]                  
Common stock, authorized     500,000,000     500,000,000 300,000,000   300,000,000
Preferred stock, shares authorized           10,000,000      
Common stock, outstanding           61,734,601 1,597,321    
Common stock, dividends per share declared           $ 0 $ 0    
Mezzanine equity, Preferred stock, authorized           10,000,000 10,000,000    
Issuance of common stock; net of issuance costs           $ 295,497,000      
Common stock, voting rights           Holders of Common Stock are entitled to one vote for each share of Common Stock held of record for the election of directors and on all matters submitted to a vote of stockholders.      
Preferred stock, voting rights           Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of Common Stock.      
Paramora Warrant Obligation                  
Subsidiary Sale Of Stock [Line Items]                  
Warrants to purchase of common stock       628,302          
Exercise price per warrant       $ 23.01          
Number of warrants exercised           0      
Underwriting Agreement                  
Subsidiary Sale Of Stock [Line Items]                  
Offering costs   $ 20,800,000              
Sale of stock, number of shares issued in transaction   16,644,737              
Sale of stock, price per share   $ 19              
Net proceeds from the underwritten offering   $ 295,500,000              
Damora Therapeutics, Inc. | Underwriting Agreement                  
Subsidiary Sale Of Stock [Line Items]                  
Offering costs   $ 20,800,000              
Sale of stock, number of shares issued in transaction   16,644,737              
Sale of stock, price per share   $ 19              
Net proceeds from the underwritten offering   $ 295,500,000              
Series A Non Voting Convertible Preferred Stock                  
Subsidiary Sale Of Stock [Line Items]                  
Preferred stock, shares authorized           200      
Preferred stock, par value           $ 0.00001      
Preferred stock, voting rights           The Series A Preferred Stock has no voting rights, except as required by law or to protect the rights of the holders of Series A Preferred Stock. No liquidation preference applies. Dividends, if declared on Common Stock, are payable to holders of Series A Preferred Stock on an as-if-converted-to-common-stock basis in the same form.      
Number of preferred stock converted into common stock         1,000        
Series A Non Voting Convertible Preferred Stock | Minimum                  
Subsidiary Sale Of Stock [Line Items]                  
Preferred Stock, issued in lieu of common stock to extent necessary to comply with percentage of limitation under Nasdaq listing rules         0.00%        
Series A Non Voting Convertible Preferred Stock | Maximum                  
Subsidiary Sale Of Stock [Line Items]                  
Preferred Stock, issued in lieu of common stock to extent necessary to comply with percentage of limitation under Nasdaq listing rules         19.99%        
Series B Non-Voting Convertible Preferred Stock                  
Subsidiary Sale Of Stock [Line Items]                  
Preferred stock, shares authorized       16,366   16,366 16,366    
Preferred stock, par value           $ 0.00001 $ 0.00001    
Preferred stock, issued           16,366 16,366    
Preferred stock, shares outstanding           16,366 16,366    
Preferred stock, voting rights           The Series B Preferred Stock does not have general voting rights; however, for so long as at least 30% of the originally issued Series B Preferred Stock remains outstanding, the Company may not, without the affirmative vote of a majority of the then-outstanding Series B shares: (i) consummate a Fundamental Transaction (as defined) or a merger or consolidation resulting in a change of control; (ii) increase the size of the board of directors; (iii) adopt, amend, or repeal certain corporate authority policies unless approved unanimously by the board of directors; or (iv) replace the Company’s registered independent public accounting firm, independent compensation consultant, or corporate counsel. The Series B Preferred Stock has no liquidation preference. Dividends, if declared on Common Stock, are payable to holders of Series B Preferred Stock on an as-if-converted basis.      
Number of preferred stock converted into common stock       1,000          
Conversion of stock, shares issued       16,366,000          
Series B Non-Voting Convertible Preferred Stock | Damora Therapeutics, Inc.                  
Subsidiary Sale Of Stock [Line Items]                  
Preferred stock, par value       $ 0.00001          
Preferred stock, issued       16,366          
Series C Non-Voting Convertible Preferred Stock                  
Subsidiary Sale Of Stock [Line Items]                  
Preferred stock, shares authorized           43,882 43,882    
Preferred stock, par value           $ 0.00001 $ 0.00001    
Preferred stock, issued       43,882   1,722 43,882    
Preferred stock, shares outstanding     1,722     1,722 43,882    
Preferred stock, voting rights           The Series C Preferred Stock does not have general voting rights, except as required by law or to protect the rights of the Series C Preferred Stock. No liquidation preference applies. Dividends, if declared on Common Stock, are payable to holders of Series C Preferred Stock on an as-if-converted basis.      
Number of preferred stock converted into common stock     42,005 1,000          
Conversion of stock, shares issued     42,005,000 43,882,000          
Stock issued during period, shares, acquisitions       4,241          
Series C Non-Voting Convertible Preferred Stock | Private Investment in Public Equity (PIPE)                  
Subsidiary Sale Of Stock [Line Items]                  
Preferred stock, issued       39,641          
Series C Non-Voting Convertible Preferred Stock | Damora Therapeutics, Inc.                  
Subsidiary Sale Of Stock [Line Items]                  
Preferred stock, par value       $ 0.00001          
Preferred stock, issued       4,241          
Series A Convertible Preferred Stock                  
Subsidiary Sale Of Stock [Line Items]                  
Preferred stock, shares outstanding               158.361  
Private Placement | Series C Non-Voting Convertible Preferred Stock | Private Investment in Public Equity (PIPE)                  
Subsidiary Sale Of Stock [Line Items]                  
Issuance of common stock in connection with offering, net of issuance costs of $20,753 (in shares)       39,641          
Stock issued during period, price per shares       $ 7,186.9          
Proceeds from issuance of preferred stock in connection with private placement, net of issuance costs       $ 267,000,000          
Offering costs       $ 18,100,000          
Private Placement | Series C Non-Voting Convertible Preferred Stock | Damora Therapeutics, Inc.                  
Subsidiary Sale Of Stock [Line Items]                  
Issuance of common stock in connection with offering, net of issuance costs of $20,753 (in shares)       39,641          
Proceeds from issuance of preferred stock in connection with private placement, net of issuance costs       $ 285,000,000          
Number of preferred stock converted into common stock       1,000          
ATM Offering Program                  
Subsidiary Sale Of Stock [Line Items]                  
Offering costs           $ 600,000      
Sale of stock, number of shares issued in transaction           1,240,400      
Remaining capacity under ATM offering program           $ 120,000,000      
Net proceeds from the underwritten offering           $ 29,300,000      
ATM Offering Program | Subsequent Event | Maximum                  
Subsidiary Sale Of Stock [Line Items]                  
Issuance of common stock; net of issuance costs $ 150,000,000                
Over-Allotment Option | Underwriting Agreement                  
Subsidiary Sale Of Stock [Line Items]                  
Sale of stock, number of shares issued in transaction   2,171,052              
Over-Allotment Option | Damora Therapeutics, Inc. | Underwriting Agreement                  
Subsidiary Sale Of Stock [Line Items]                  
Sale of stock, number of shares issued in transaction   2,171,052